Allogene Therapeutics ALLO 深 沪
等待开盘 10-02 09:30:00 美东时间
1.24
0.000
0.00%
华盛通- 最 高1.27
- 今 开1.24
- 成交量 240.32万股
- 最 低 1.23
- 昨 收 1.24
- 总市值 2.72亿
- 52周最高 3.78
- 市盈率 静 --
- 换手率 1.10%
- 52周最低 0.8621
- 委 比 28.10%
- 总股本 2.19亿
- 历史最高 55.00
- 量 比 0.72
- 振 幅 3.23%
- 历史最低 0.8621
- 每 手 1
- 风险率 0.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多In Vivo与Allo CAR-T：谁先攻克商业化堡垒？
（来源：抗体圈） 2020年前后，同种异体CAR-T（AlloCAR-T）疗法风头无两。作为传统自体CAR-T的升级方向，它承诺摆脱“一人一药”的定制化...
09-22 18:46
Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025
Autolus Therapeutics announced the online publication of an abstract for their ACR Convergence 2025 poster presentation, showcasing updated data from the CARLYSLE study on obe-cel for severe refractory systemic lupus erythematosus (srSLE). The Phase I study demonstrates a manageable safety profile with no dose-limiting toxicities or severe CRS/ICANS, alongside reductions in SLEDAI-2K scores and clinical benefit in all patients, including complete...
09-16 12:05
Enlivex CEO Oren Hershkovitz Issues Shareholder Letter Highliting Phase IIa Topline Results For Allocetra In Knee Osteoarthritis And Clinical Development Roadmap
Dear fellow shareholders,I would like to take this opportunity to provide you with our perspective on our recent Phase IIa (ENX-CL-05-001) 3-month topline data readout for Allocetra™ in patients with
09-11 20:11
Allogene Therapeutics Announces Participation in Upcoming Investor Conference
Allogene Therapeutics will participate in Citi's 2025 Biopharma Back to School Summit on September 3 at 7:30AM PT/10:30AM ET. Live webcasts and a replay will be available on the company's website under the Investors section. Allogene focuses on developing allogeneic CAR T products for cancer and autoimmune diseases to deliver scalable, ready-to-use cell therapies.
08-27 12:30
Marker Therapeutics Stock Drops After Report About Lymphoma Treatment
Marker Therapeutics reports strong safety and efficacy data for MT-601 in lymphoma patients, with durable responses and no serious adverse events.
08-27 00:34
Allogene Therapeutics Advances in CAR T Cell Therapy
Allogene Therapeutics ( ($ALLO) ) has released its Q2 earnings. Here is a break...
08-14 11:57
Allogene Therapeutics Q2 EPS $(0.23) Beats $(0.28) Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.28) by 18.15 percent. This is a 34.29 percent increase over losses of $(0.35) per share
08-14 04:38
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
A Look at Allogene Therapeutics's Upcoming Earnings Report
Allogene Therapeutics (NASDAQ:ALLO) is preparing to release its quarterly earni...
08-13 02:02
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
Allogene Therapeutics will report its Q2 2025 financial results and provide a business update on August 13, 2025, followed by a live webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. The listen-only webcast will be available at www.allogene.com under the Investors tab, with a replay accessible for 30 days. To ask questions during the call, registration is required via a provided link to receive a personal PIN. Allogene, headquartered in S...
08-06 12:30
